MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Enters Updated LOI to Acquire 51% of Mobile Game Developer Csfctech

 Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its entry into an updated letter of intent (“LOI”). Under the terms of the LOI, BHAT will acquire the control of 51% of Fuzhou Csfctech Co. Ltd. (“Csfctech”) and its two subsidiaries through the direct acquisition of 51% of the outstanding shares of its offshore holding company. Csfctech is a developer and distributor of mobile games with an international user base across Mainland China, Japan, Taiwan, the United Arab Emirates and Africa. “We believe that this transaction represents a significant development in our strategy and ability to rollout a wider breath of augmented reality and mobile games to our growing audience in China,” BHAT CEO Xiaodong Chen said in the news release. “Csfctech’s business covers more than 100 games available on a number of different platforms and maintains a strong following of customers based in Asia and Africa. Through this acquisition, not only can we integrate the product development technology, operation and distribution resources of Csfctech, but also our combined resources may help strengthen the available distribution channels. In addition, we expect to leverage our combined expertise to improve the product structure and enhance the overall revenue scale and marketing capabilities.”

Click here to view the full press release

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Creatd Inc. (NASDAQ: CRTD) Appoints New COO to Lead Growth Strategy, Manage Partnership Initiatives

 Creatd (NASDAQ: CRTD, CRTDW), the parent company and creator of the Vocal platform, today announced the appointment of Laurie Weisberg as its new chief operating officer. Weisberg currently sits on Creatd’s board of directors and will lead the company’s sales team in the execution of its growth strategy and manage all strategic partnership initiatives. This appointment aligns with Creatd’s 2021 plans to broaden and scale its product line and revenues, including Vocal for Brands, Seller’s Choice, and Vocal+ paid subscriptions. “I have closely observed the Creatd team over the last year, particularly since I assumed my role as a member of the board of directors over the summer,” said Weisberg in the news release. “It is clear that the team’s ability to unleash the power of the network in delivering valuable content for audiences, while at the same time helping brands drive their growth by leveraging the highly engaged Vocal community and rich first-party data, makes Creatd a unique brand with a global proposition. As COO, I look forward to working closely with Jeremy and the rest of the management team to continue to build Creatd’s scalable and profitable business lines.”

To view the full press release, visit https://ibn.fm/GVOEZ

About Creatd Inc.

Creatd, the parent company and creator of the Vocal platform, empowers content creators and brands through technology and data-driven innovation. Creatd identifies opportunities within the digital platform and content monetization space, and leverages them through the company’s proprietary Vocal technology, as well as through complementary digital businesses including Vocal for Brands and Seller’s Choice. Since launching in 2016, Vocal has become home to over 700,000 content creators and brands of all shapes and sizes, attracting audiences across its network of wholly owned and operated communities. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

 VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To adequately address the growing problem of workplace stress and anxiety both during and after the COVID-19 pandemic – and the physical and mental health consequences associated with it – a multi-pronged approach is needed,” states Singh in the article. “This approach should include the provision of additional mental/emotional health support from employers in the form of employee assistance programs (‘EAPs’), as well as novel approaches to psychotherapy and fundamentally different medications by mental health professionals.”

To view the full article, visit https://ibn.fm/XJCvn

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication

 VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the article, VistaGen’s CEO Shawn Singh discussed the company’s ongoing efforts to treat and help manage the anxiety symptoms provoked by COVID-19 and other triggers, anxiety-related disorders initially in subjects suffering from Social Anxiety Disorder (“SAD”), as well as the FDA’s consensus on the design of the company’s pivotal Phase III study of PH94B. The piece quotes Singh, who states, “Now more than ever, patients around the world need new medications that go beyond the standard of care for anxiety, depression and suicidal ideation. For patients who have a debilitating mental health condition, our goal with PH94B for SAD, as well as for several other anxiety disorders, is to develop and offer an innovative, life-changing treatment that goes beyond the current standard of care and allows patients to manage their anxiety to the point where they are able to live their lives as the ideal version of themselves—a crucial driver for everything we do.”

To view the full article, visit https://ibn.fm/Ym21x

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

 

• Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients
• Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients
• POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid clinical decision-making and lead to better health outcomes. The National Cancer Institute (“NCI”) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m) – a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector “AI hubs” designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).

A primary goal of precision cancer medicine is the accurate prediction of optimal drug therapies based upon the personalized molecular profiles of patient tumors; ideally, such predictions are based upon well-established molecular cause-and-effect relationships that are disrupted in cancer calls (https://ibn.fm/LQvQX). The foundation of these accurate predictions is built upon extensive bodies of data, with the volume of cancer-relevant data being generated and electronically stored on a daily basis vastly exceeding what could even be imagined only a few decades ago. As such, the search for significant correlations within cancer-relevant “big” datasets is a task which is ideally suited for artificial intelligence and machine learning-based approaches.

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its unique real-world longitudinal data of drug-response and genomic profiles gathered from more than 150,000 de-identified cancer cases. Through its subsidiary Helomics, POAI is seeking to bring this cutting-edge technology to cancer research, where it is working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which is able to grow the patient’s heterogeneous tumor sample in the laboratory, enabling oncologists to develop a patient-specific treatment plan (https://ibn.fm/byGJI).

Going forward, the use of artificial intelligence will help oncological researchers quickly understand how cancer cells become resistant to anti-cancer drugs, which can help improve drug development and adjust drug use. The technology can also be used to manage the use of chemotherapy drugs and predict a patient’s tolerance levels, thus allowing for chemotherapy regimens to be optimized. In the future, by leveraging Predictive Oncology’s AI-driven solutions, doctors will be able to make better-informed treatment decisions, thus reducing the need for unnecessary or poorly targeted treatments and improving patient outcomes.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI        

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

 

• Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
• CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
• Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/fqDvu). 

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Acquires LD Micro, Accelerates Adoption of SaaS Data Management Platform

 

• SRAX recently closed acquisition of LD Micro, leading micro-cap information portal
• LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash
• Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform
• Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020

SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro a wholly-owned subsidiary of SRAX while maintaining founder Christopher Lahiji as president and appointing him to SRAX’s board of directors.

The move comes during a rapid growth period for Sequire, SRAX’s data analytics SaaS platform. Geared towards the investment industry, Sequire unlocks data and insight for public companies that can be used to activate marketing campaigns to engage both new, existing and potential investors.

Prior to acquiring LD Micro, SRAX had witnessed strong early success with Sequire. The platform doubled its user base to over one million investors and traders in two months (https://ibn.fm/j6oNa), in addition to posting Q2 earnings that showed a 29% increase in year-over-year revenue. The acquisition of LD Micro – a leading brand in the provision of exclusive information on micro-cap North American stocks – is expected to accelerate the adoption of Sequire while enhancing LD Micro’s own digital assets.

Sequire helps public companies gain insights on the activities of both retail and institutional investors, providing critical actionable data to activate successful campaigns aimed to increase engagement with current investors while attracting new ones. Sequire’s application suite is currently being used by over 91 companies to harness the power of their data through the use of tools that leverage investor intelligence and outreach, track warrants, engage users through surveys, and promote events and roadshows.

“The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in recent statements (https://ibn.fm/Mzz1z). “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.”

“Over 1,500 companies have presented at LD Micro’s events since 2008, and almost all of them would be immediate beneficiaries of this technology,” he continued.

The acquisition of LD Micro is expected to be immediately accreditive to SRAX’s operations. The recent LD 500 conference, held online in early September, included presentations from hundreds of companies across a wide range of industries in addition to featuring keynotes with some of the most prominent figures in the micro-cap world.

The company continues to leverage the growing demand for quantifiable and detailed consumer data by creating specialized tools that empower companies to reveal core consumers and their characteristics across a wide range of industries.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Announces Contract, Plans to Begin Production Deployment of PrintRite3D Software

 Sigma Labs (NASDAQ: SGLB), a leading developer of in-process, quality-assurance software for the commercial 3D-printing industry, has been awarded a contract by a leading global energy technology provider. The contract, which was finalized after a successful Rapid Test and Evaluation (“RTE”) program, calls for beginning production deployment of PrintRite3D(R) in-process quality assurance software. During the RTE, engineers worked closely with Sigma’s engineering team to evaluate issues involved in the customer’s application of SGLB’s proprietary PrintRite3D technology, specifically as it pertained to running the technology on an EOS single-laser machine and an SLM dual-laser machine. The announcement of this contract follow SGLB’s recent sale of an initial PrintRite3D production system to Mitsubishi Heavy Industries. “The conversion from our RTE program to beginning production deployment is a testament to the traction our enabling technology is garnering in the additive manufacturing industry,” Sigma Labs CEO Mark Ruport stated in the press release.

To view the full press release, visit https://ibn.fm/a1bXl

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing For more information about the company, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html